Trending...
- World Sleep Day, why do we celebrate?
- Fridge Art Fair New York City May 2023
- California: Governor Newsom Announces Historic Transformation of San Quentin State Prison
QView's AI-QVCAD, combined with GEHC's ABUS breast ultrasound system, potentially accelerates the acceptance of 3D breast ultrasound as supplemental screening for women with dense breast tissue.
LOS ALTOS, Calif. - Californer -- QView, Inc., a medical technology leader providing artificial intelligence systems for breast cancer detection, and GEHC have signed a distribution agreement where QView Medical's AI-QVCAD software system will be added to GEHC's portfolio of breast imaging AI solutions for the detection and diagnosis of breast cancer.
Under the definitive agreement, GEHC will market and sell AI-QVCAD for its ABUS – Automated Breast Ultrasound System.
"QView working with GEHC is an excellent example of two organizations leveraging our mutual strengths and technological capabilities to provide a multimodality approach for breast screening. There is no single imaging screening solution," said Bob Wang, President, and CEO of QView, Inc
Mammography misses one-third of the cancers in screening women with dense breast tissue; breast density increases women's cancer risk 4-6 times, affecting more than 40 percent of women1. Earlier cancer detection is critical to increased survival rates, improved patient care, and reduced cost of care.
More on The Californer
The ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. Adding AI-QVCAD software to the ABUS system is a powerful tool in detecting breast cancers earlier when they are more treatable, less invasive treatments, and improve patient quality of life.
Clinicians can now review AI-QVCAD results on the Invenia ABUS Viewer, streamlining clinical workflow and reducing the reading time by up to 33%2 while improving clinical outcomes with up to 93%3 sensitivity for lesion detection.
QView Medical supports all efforts to raise awareness of breast density as a significant risk factor - #DENSEBREASTINFO #AREYOUDENSE. QView supports passage of #FINDITEARLY Federal bill requiring health insurers to reimburse for screening and diagnostic breast ultrasound exams – no copay, no deductible.
About QView Medical, Inc.
QView Medical develops AI image-analysis systems for 3D Automated Breast Ultrasound Systems ABUS). The QView team has been the leader in AI technologies and breast cancer detection for over twenty-five years, including developing R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS, and QView AI QVCAD. Visit our website www.qviewmedical.com for more information.
More on The Californer
--
Under the definitive agreement, GEHC will market and sell AI-QVCAD for its ABUS – Automated Breast Ultrasound System.
"QView working with GEHC is an excellent example of two organizations leveraging our mutual strengths and technological capabilities to provide a multimodality approach for breast screening. There is no single imaging screening solution," said Bob Wang, President, and CEO of QView, Inc
Mammography misses one-third of the cancers in screening women with dense breast tissue; breast density increases women's cancer risk 4-6 times, affecting more than 40 percent of women1. Earlier cancer detection is critical to increased survival rates, improved patient care, and reduced cost of care.
More on The Californer
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Array Technologies, Inc. (ARRY) on Behalf of Investors
- Sip Social Co. Partners With Apé Canada For Supply Of Piaggio Apé's
- California Woman Battling Alopecia Launches Online Wig, Hair Accessories Store
- Orange County Business Journal Ranks Snell & Wilmer in the Top 10 Largest Law Firms in Orange County
- Medicare Advantage Agent Commissions Increase For 2023
The ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. Adding AI-QVCAD software to the ABUS system is a powerful tool in detecting breast cancers earlier when they are more treatable, less invasive treatments, and improve patient quality of life.
Clinicians can now review AI-QVCAD results on the Invenia ABUS Viewer, streamlining clinical workflow and reducing the reading time by up to 33%2 while improving clinical outcomes with up to 93%3 sensitivity for lesion detection.
QView Medical supports all efforts to raise awareness of breast density as a significant risk factor - #DENSEBREASTINFO #AREYOUDENSE. QView supports passage of #FINDITEARLY Federal bill requiring health insurers to reimburse for screening and diagnostic breast ultrasound exams – no copay, no deductible.
About QView Medical, Inc.
QView Medical develops AI image-analysis systems for 3D Automated Breast Ultrasound Systems ABUS). The QView team has been the leader in AI technologies and breast cancer detection for over twenty-five years, including developing R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS, and QView AI QVCAD. Visit our website www.qviewmedical.com for more information.
More on The Californer
- UCLA/Luskin Orthopaedic Institute for Children to Host Professional Conference and Family Forum for National Cerebral Palsy Awareness Day on March 25, 2023
- Back in Action Wraps Production Despite Alleged On-Set Drama Involving Jamie Foxx
- City of Long Beach Recognizes Tsunami Awareness Week March 27 through 31
- Long Beach Airport Director Cynthia Guidry Honored by Conference of Minority Transportation Officials
- Sortium Joins UC Berkeley's Blockchain Xcelerator Program
--
- Boyd, et al, NEJM Jan 2007
- Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women with Dense Breast Tissue (Yulei Jiang). Read More: https://www.ajronline.org/doi/10.2214/AJR.18.19516
- Performance and Reading Time of Automated Breast US with or without Computer-aided Detection. Read More: https://pubs.rsna.org/doi/10.1148/radiol.2019181816
Source: Qview Medical, Inc.
0 Comments
Latest on The Californer
- Southeast Ventura County YMCA National Day of Prayer Breakfast Seeks Sponsors
- RE/MAX Signature Earns Top Regional Award
- Prime Healthcare Celebrates Patient Safety Excellence Recognition from Healthgrades
- Long Beach to Offer Free Youth Recreation Program in Local Parks During School Spring Break April 10-14
- Sobreo Launches California Cocktails Campaign to Elevate Los Angeles Bar Menus with Health-Conscious & Inclusive Drinking Options
- The Mogharebi Group Opens Offices in Las Vegas and Albuquerque
- David Goran answers when to self insure
- Long Beach: Community Invited to Learn About and Provide Input on Local Priorities for Federal Grant Funding
- Introducing Beauty Meditation - A Mobile App for Skin Treatment and Anti-Aging through Stress Relief
- Wohler releases out-of-band configuration tools for Riedel 2110 SFP's
- Wrap up Women's History Month with the tropical sounds of Jessica Medina's "Morir Soñando"
- Keysight Introduces Battery Emulation and Profiling Solution for IoT Devices
- Transtector Releases Outdoor, 10 GbE, PoE++ Data Surge Protector
- Levinger Regens Announces New Initiative to Improve Hydrogen Carbon Intensity
- Eve Wellness, a SF Breast Ultrasound Screening Clinic supports the recent FDA updates to the guidelines to inform women about breast density
- Expert tip: Private Jet Engine Maintenance Program - Pros and Cons for Preowned Jet Buyers
- Gaming and entertainment company Spinrack Corporation, appoints Jesse Norton as Chief Marketing Officer
- IGT Unveils New Class II Games and Next-Generation Innovations at 2023 Indian Gaming Tradeshow & Convention
- Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division
- VMware Unlocks Limitless Possibilities for Partners to Capture the Multi-Cloud Opportunity